Recovery of bitumen from oil sands in northern Alberta, Canada, occurs by surface mining or in situ thermal recovery, and both methods produce toxic oil sands process-affected water (OSPW). A new characterization strategy for surface mining OSPW (sm-OSPW) and in situ OSPW (is-OSPW) was achieved by combining liquid chromatography with orbitrap mass spectrometry (MS). In electrospray positive and negative ionization modes (ESI(+)/ESI(-)), mass spectral data were acquired with high resolving power (RP > 100,000-190,000) and mass accuracy (<2 ppm). The additional chromatographic resolution allowed for separation of various isomers and interference-free MS(n) experiments. Overall, ∼3000 elemental compositions were revealed in each OSPW sample, corresponding to a range of heteroatom-containing homologue classes: Ox (where x = 1-6), NOx (where x = 1-4), SOx (where x = 1-4), NO₂S, N, and S. Despite similarities between the OSPW samples at the level of heteroatom class, the two samples were very different when considering isomer patterns and double-bond equivalent profiles. The chromatographic separations also allowed for confirmation that, in both OSPW samples, the O₂ species detected in ESI(-) (i.e., naphthenic acids) were chemically distinct from the corresponding O₂ species detected in ESI(+). In comparison to model compounds, tandem MS spectra of these new O₂ species suggested a group of non-acidic compounds with dihydroxy, diketo, or ketohydroxy functionality. In light of the known endocrine-disrupting potential of sm-OSPW, the toxicity of these O₂ species deserves attention and the method should be further applied to environmental forensic analysis of water in the region.

Acute toxicity of oil sands process-affected water (OSPW) is caused by its complex mixture of bitumen-derived organics, but the specific chemical classes that are most toxic have not been demonstrated. Here, effects-directed analysis was used to determine the most acutely toxic chemical classes in OSPW collected from the world's first oil sands end-pit lake. Three sequential rounds of fractionation, chemical analysis (ultrahigh resolution mass spectrometry), and acute toxicity testing (96 h fathead minnow embryo lethality and 15 min Microtox bioassay) were conducted. Following primary fractionation, toxicity was primarily attributable to the neutral extractable fraction (F1-NE), containing 27% of original organics mass. In secondary fractionation, F1-NE was subfractionated by alkaline water washing, and toxicity was primarily isolated to the ionizable fraction (F2-NE2), containing 18.5% of the original organic mass. In the final round, chromatographic subfractionation of F2-NE2 resulted in two toxic fractions, with the most potent (F3-NE2a, 11% of original organic mass) containing predominantly naphthenic acids (O2(-)). The less-toxic fraction (F3-NE2b, 8% of original organic mass) contained predominantly nonacid species (O(+), O2(+), SO(+), NO(+)). Evidence supports naphthenic acids as among the most acutely toxic chemical classes in OSPW, but nonacidic species also contribute to acute toxicity of OSPW.

No abstract

Bombesin/gastrin-releasing peptides (BN/GRP) were shown to bind selectively to cell surface receptors, stimulating the growth of various types of malignancies in murine and human models. The novel BN/GRP synthetic receptor antagonist, RC-3095, was able to produce long-lasting tumor regressions in murine and human tumor models in vitro and in vivo. Animal toxicology studies showed no detectable organ toxicity apart from local irritation at the injection site. The purpose of this study was to determine the safety and feasibility of the administration of RC-3095 by daily subcutaneous injections in patients with advanced and refractory solid malignancies. Twenty-five patients received RC-3095 once or twice-daily at doses ranging from 8 to 96 ug/kg. Dose was escalated in groups of 3-5 patients per dose level. The only toxicity observed was local discomfort in the injection site at the highest doses. A single dose administration of RC-3095 at the highest dose level (96 ug/kg) was tested in a clearly hypergastrinemic individual with the Zollingen-Ellison syndrome and produced a decrease in plasma gastrin down to 50% of basal levels in 6 h. There was no objective tumor responses in patients included in the study. A short-lasting minor tumor response was observed in a patient with a GRP-expressing progressive medullary carcinoma of the thyroid. Due to problems with the analytical method, plasma pharmacokinetic data was obtained only from two patients included at the highest dose level. In these patients, RC-3095 reached plasma concentrations >100 ng/mL for about 8 h, which were within therapeutic levels on the basis of prior data obtained in mice and rats. The plasma elimination half-life was between 8.6-10.9 h. Due to the occurrence of local toxicity at the injection site, the dose escalation procedure could not be fully evaluated up to a maximum tolerated dose. Thus, a recommended dose of RC-3095 for Phase II trials could not be clearly established. Considering the novelty of its mechanism of action and impressive preclinical anti-tumor activity, further studies exploiting new formulations of RC-3095 for human use, such as slow-release preparations, and analogues with a more favorable pharmacokinetics are warranted.

No abstract